Hypothesis: The age‑associated decline in NAD+ is not only a downstream effect of senescent‑cell‑driven CD38 upregulation but also actively reinforces a HIF‑1α‑dependent transcriptional program in tissue‑resident macrophages that further amplifies CD38 expression, creating a self‑sustaining inflammatory‑metabolic axis.

Rationale from existing work

• Senescent cells increase CD38 expression on macrophages, driving NAD+ catabolism ([1][2]).
• CD38 knockout preserves NAD+ and protects against mitochondrial dysfunction ([1]).
• Low NAD+ promotes DNA damage and mitochondrial dysfunction that foster senescence ([5]), suggesting a feedback loop.

Novel mechanistic insight We propose that falling NAD+ alters the NAD+/NADH ratio, stabilizing HIF‑1α even under normoxic conditions in macrophages. HIF‑1α then binds hypoxia‑response elements in the Cd38 promoter, boosting its transcription independent of senescence‑derived cytokines. This creates a feed‑forward loop: senescent cells → cytokines → modest CD38 rise → NAD+ loss → HIF‑1α stabilization → amplified CD38 → further NAD+ depletion → enhanced senescence.

Testable predictions

1. In aged wild‑type mice, macrophage HIF‑1α protein levels will be elevated and inversely correlated with tissue NAD+.
2. Macrophage‑specific HIF‑1α knockout (Hif1a^fl/fl Cx3cr1^Cre) will prevent age‑related CD38 up‑regulation despite normal senescent‑cell burden.
3. These mice will retain higher NAD+ levels, show reduced SASP markers, and exhibit improved metabolic health compared with littermate controls.
4. Pharmacologic HIF‑1α inhibition (e.g., with PX-478) administered after senescent‑cell clearance will block the rebound of CD38 and NAD+ loss.

Experimental design

• Groups: young (3 mo), aged WT (24 mo), aged macrophage‑HIF‑1α KO, aged WT + senolytic (dasatinib + quercetin), aged KO + senolytic.
• Readouts: flow cytometry for CD38^+ F4/80^+ macrophages, LC-MS NAD+/NADH, ELISA for IL-6, IL-1beta, SASP, histology for fibrosis, grip strength and treadmill endurance.
• Timeline: treat senolytics for 2 weeks, then monitor for 8 weeks.

Falsifiability If macrophage HIF‑1α loss does not reduce CD38 expression or NAD+ levels in aged mice, or if NAD+ remains low despite HIF‑1α deficiency, the hypothesis is falsified. Conversely, a rescue of NAD+ and decline in senescence markers would support the proposed loop.

Implications Targeting the HIF‑1α‑CD38 axis could decouple NAD+ depletion from senescent‑cell burden, allowing NAD+ boosters to act on healthy tissue without risking SASP amplification. This reframes the NAD+ "budget cut" as a controllable metabolic switch rather than an inevitable consequence of aging.